GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » Degree of Operating Leverage

CGTX (Cognition Therapeutics) Degree of Operating Leverage : 0.00 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Cognition Therapeutics does not have enough data to calculate Degree of Operating Leverage.


Cognition Therapeutics Degree of Operating Leverage Historical Data

The historical data trend for Cognition Therapeutics's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics Degree of Operating Leverage Chart

Cognition Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial - - - - -

Cognition Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cognition Therapeutics's Degree of Operating Leverage

For the Biotechnology subindustry, Cognition Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognition Therapeutics's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Cognition Therapeutics's Degree of Operating Leverage falls into.


;
;

Cognition Therapeutics Degree of Operating Leverage Calculation

Cognition Therapeutics's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -33.28 (Mar. 2025) / -28.74 (Mar. 2024) - 1 )/( 0 (Mar. 2025) / 0 (Mar. 2024) - 1 )
=0.158/
=N/A***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Cognition Therapeutics  (NAS:CGTX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Cognition Therapeutics Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognition Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2500 Westchester Avenue, Purchase, NY, USA, 10577
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Executives
Lisa Ricciardi director, officer: CEO & President C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
John Brendan Doyle officer: Chief Financial Officer C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Anthony Caggiano officer: Chief Medical Officer C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone director C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l. director 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace director C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107